Cassava Sciences, Inc.
SAVA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $5 | $14 | $21 |
| Gross Profit | -$0 | -$5 | -$14 | -$21 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $5 | $14 | $21 |
| G&A Expenses | $0 | $9 | $8 | $1 |
| SG&A Expenses | $8 | $9 | $8 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $26 | -$11 | -$13 |
| Operating Expenses | $12 | $40 | $11 | $9 |
| Operating Income | -$12 | -$45 | -$25 | -$29 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $2 |
| Pre-Tax Income | -$11 | -$44 | -$23 | -$28 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$44 | -$23 | -$28 |
| % Margin | – | – | – | – |
| EPS | -0.22 | -0.92 | -0.48 | -0.57 |
| % Growth | 76.1% | -91.7% | 15.8% | – |
| EPS Diluted | -0.22 | -0.92 | -0.48 | -0.57 |
| Weighted Avg Shares Out | 48 | 48 | 48 | 48 |
| Weighted Avg Shares Out Dil | 48 | 48 | 48 | 48 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11 | -$14 | -$21 | -$19 |
| % Margin | – | – | – | – |